Updated

Updated · pacificresearch.org · Jul 27

Trump Administration Moves to Expand Medicare Obesity Drug Coverage After Decades-Long Ban

Updated

Updated · pacificresearch.org · Jul 27

Trump Administration Moves to Expand Medicare Obesity Drug Coverage After Decades-Long Ban

Q: With Medicare's temporary $50 copay for obesity drugs now active, what happens to seniors' treatments when the program ends in 2027?

When the Medicare GLP-1 Bridge ends on Dec. 31, 2027, seniors do not have guaranteed continued access to the $50 obesity-drug copay. Unless CMS extends the bridge again, launches a new Medicare pathway, or Congress changes the law, treatment would likely stop being covered for obesity alone under this temporary program. That creates a practical risk for patients because the bridge operates outside standard Part D and the long-standing Medicare statutory ban on drugs prescribed specifically for weight loss still exists. Some beneficiaries could keep getting a GLP-1 only if they qualify for ordinary Part D coverage for another FDA-approved use, such as type 2 diabetes or certain cardiovascular indications. In those cases, coverage would depend on the drug, diagnosis, and plan rules, not the bridge’s flat $50 price. CMS had planned a broader BALANCE model, but Medicare implementation has been delayed until at least 2028 because of limited plan participation. That leaves a gap after 2027 unless federal officials act. Another possible fix is legislation such as the Treat and Reduce Obesity Act, which would explicitly allow Medicare Part D to cover FDA-approved obesity drugs. For patients, the key issue is continuity: GLP-1 medicines often need to be taken long term, and evidence shows many people regain weight after stopping. Seniors using the bridge should expect uncertainty after 2027 and may need to discuss backup options with their doctors well before the program expires.

3 articles · Updated · pacificresearch.org · Jul 27

The Trump administration has begun reversing Medicare’s longstanding policy of excluding drugs prescribed specifically for obesity treatment.
Federal law had barred that coverage for decades even as Medicare continued paying billions of dollars each year for obesity-linked illnesses including heart disease, diabetes, kidney disease and cancer.
The shift targets a basic policy contradiction: the program covered the costly consequences of excess weight while refusing to pay for medicines aimed at the underlying disease.
If carried through, the change would mark a broader rethinking of obesity within Medicare—from a condition excluded from drug coverage to one treated more directly.